Improved detection of HCV Infection in hemodialysis patients using a new HCV RNA qualitative assay: experience of a transplant center
| Autor: | Mehbobeh Aghajani, S. Aswad, Robert Mendez, Lorraine Comanor, H. Shidban, Ralph Mendez, N Khan |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Genotype
Waiting Lists Transcription-mediated amplification Hepatitis C virus Hepacivirus Population medicine.disease_cause Polymerase Chain Reaction Sensitivity and Specificity Flaviviridae Renal Dialysis Virology medicine Humans education education.field_of_study medicine.diagnostic_test biology business.industry virus diseases Hepatitis C medicine.disease biology.organism_classification Kidney Transplantation digestive system diseases Transplantation Infectious Diseases Immunoassay RNA Viral business |
| Zdroj: | Journal of Clinical Virology. 30:175-182 |
| ISSN: | 1386-6532 |
| DOI: | 10.1016/j.jcv.2003.10.004 |
| Popis: | Background: Hepatitis C virus (HCV) is frequently a silent infection in hemodialysis (HD) patients with a prevalence of 8–10%. Improving HCV detection in this population prior to transplantation is critical both for infection control and optimal patient care. Objectives: To assess the current HCV testing practice of the National Institute for Transplantation (PCR testing of enzyme immunoassay (EIA) positive HD patients) by evaluating a subset of EIA positive and EIA negative samples with the VERSANT ® HCV RNA Qualitative Assay based on transcription mediated amplification (HCV Qual (TMA)) (sensitivity ≤9.6IU/ml) and in-house PCR (HCV Qual (PCR)) (sensitivity ∼149IU/ml). Study design: 2321 HD patients were screened by Abbott HCV EIA 2.0. A subset of 80/169 E IA positive samples and 100/2152 EIA negative samples were tested by both assays. TMA/PCR discordant samples were genotyped. Results: PCR and TMA gave concordant results in 67/80 (83.8%) of EIA positive samples. 11/80 (14.7%) were reactive by HCV Qual (TMA), but not by HCV Qual (PCR); 2/80 (2.7%) were reactive by HCV Qual (PCR), but not by HCV Qual (TMA). 2/100 (2%) EIA negative samples were reactive and 95/100 (95%) were non-reactive by both assays. Three (3%) were only HCV Qual (TMA) reactive. 11/14 TMA+/PCR—samples with sufficient volume were genotyped. Conclusions: HCV Qual (TMA) identified active HCV infection in more EIA positive and EIA negative patients than HCV Qual (PCR) and should be part of our testing algorithm. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect